PRME

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.19
Percentage change -9.95	%

Data

Timeframe

Analyst Consensus (10)Strong BuyFeb 28, 2025

Low Target$6.00+248.84%Feb 2026

Avg Target$12.90+650.00%Feb 2026

High Target$19.00+1,004.65%Feb 2026

Target Price and Recommendations

12 Analysts

Strong Buy: 11

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Consensus: Strong Buy (1.17)

Feb 28, 2025

EPS Performance and Forecast

Currency: USD	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25
Estimate	-0.41	-0.42	-0.43	-0.56	-0.45	-0.39	-0.39	-0.35	-0.31	-0.32	-0.31	-0.29
# of Analysts	5	6	8	8	10	13	13	10	10	10	10	10
Reported	-0.44	-0.47	-0.55	-0.72	-0.44	-0.46	-0.44	-0.31	—	—	—	—
Surprise	-0.03 6.18%	-0.05 11.03%	-0.12 26.67%	-0.16 29.50%	0.01 -3.28%	-0.07 18.01%	-0.05 14.20%	0.04 -11.61%	—	—	—	—

GAAP EPS Performance and Forecast

Currency: USD	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25
Estimate	-0.41	-0.45	-0.51	-0.56	-0.49	-0.42	-0.35	-0.28	-0.37	-0.37	-0.38	-0.38
# of Analysts	1	2	2	2	4	4	5	5	3	3	3	3
Reported	-0.44	-0.46	-0.58	-0.72	-0.44	-0.46	-0.44	-0.32	—	—	—	—
Surprise	-0.03 6.74%	-0.01 3.18%	-0.07 13.48%	-0.16 28.83%	0.05 -9.77%	-0.04 10.29%	-0.09 27.17%	-0.04 15.94%	—	—	—	—

Revenue Performance and Forecast

Currency: USD	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25
Estimate	0.00	0.00	1.67M	5.71M	1.92M	1.63M	7.09M	6.78M	4.99M	5.01M	5.05M	5.16M
# of Analysts	3	4	6	7	9	10	11	9	9	9	9	9
Reported	0.00	0.00	0.00	0.00	591.00K	0.00	204.50K	2.20M	—	—	—	—
Surprise	0.00	0.00	-1.67M -100.00%	-5.71M -100.00%	-1.33M -69.25%	-1.63M -100.00%	-6.89M -97.12%	-4.59M -67.63%	—	—	—	—

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: VTI ARKG ARKK IWM VXF IWO VTWO SCHA IBB VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.70	Insider Own	60.42%	Shs Outstand	131.16M	Perf Week	-25.22%
Market Cap	225.60M	Forward P/E	-	EPS next Y	-1.19	Insider Trans	0.00%	Shs Float	51.92M	Perf Month	-24.56%
Income	-195.88M	PEG	-	EPS next Q	-0.31	Inst Own	31.20%	Short Float	34.75%	Perf Quarter	-46.58%
Sales	2.98M	P/S	75.70	EPS this Y	28.27%	Inst Trans	-12.28%	Short Ratio	16.21	Perf Half Y	-57.00%
Book/sh	1.17	P/B	1.47	EPS next Y	-0.90%	ROA	-48.54%	Short Interest	18.04M	Perf Year	-78.58%
Cash/sh	1.45	P/C	1.18	EPS next 5Y	10.72%	ROE	-136.88%	52W Range	1.83 - 8.27	Perf YTD	-41.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-124.13%	ROI	-102.92%	52W High	-79.20%	Beta	1.93
Dividend TTM	-	Quick Ratio	5.58	Sales past 5Y	-20.00%	Gross Margin	-105.43%	52W Low	-6.01%	ATR (14)	0.25
Dividend Ex-Date	Sep 10, 2019	Current Ratio	5.58	EPS Y/Y TTM	20.58%	Oper. Margin	-6787.36%	RSI (14)	29.87	Volatility	13.12% 11.12%
Employees	214	Debt/Eq	0.27	Sales Y/Y TTM	-	Profit Margin	-6566.61%	Recom	1.17	Target Price	12.90
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	47.11%	Payout	-	Rel Volume	1.83	Prev Close	1.91
Sales Surprise	-67.63%	EPS Surprise	11.61%	Sales Q/Q	-	Earnings	Feb 28 BMO	Avg Volume	1.11M	Price	1.72
SMA20	-31.06%	SMA50	-36.56%	SMA200	-57.38%	Trades		Volume	2,039,856	Change	-9.95%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

Feb-28-25 08:00AM	Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 08:00AM	Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
06:25AM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 08:00AM	Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences (GlobeNewswire) +10.00%
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
Sep-19-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-07-23 04:01PM	Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.66%
Jul-25-23 07:45AM	2 Cathie Wood Stocks That Could Be Hidden Gems (Motley Fool)
Jun-29-23 08:46AM	We're Hopeful That Prime Medicine (NASDAQ:PRME) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-23 08:00AM	Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome (GlobeNewswire)
Jun-02-23 10:15AM	Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought (Motley Fool) +9.15%
May-31-23 08:00AM	Prime Medicine to Present at Investor Conferences in June (GlobeNewswire)
May-26-23 09:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
May-17-23 04:05PM	Prime Medicine to Present at Virtual Investor Conferences in May (GlobeNewswire)
06:00AM	Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.61%
Mar-27-23 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days (GlobeNewswire) +5.89%
Mar-09-23 08:00AM	Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 08:00AM	Prime Medicine to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-20-23 05:56AM	We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities (GlobeNewswire)
Jan-03-23 08:00AM	Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.60%
Nov-01-22 04:13PM	After Prime Medicine, What's the Next Gene Editing IPO? (TheStreet.com) +12.22%
Oct-24-22 05:30PM	Prime Medicine Announces Closing of Upsized Initial Public Offering (GlobeNewswire) +5.59%
Oct-20-22 12:45PM	UPDATE 1-Biotech firm Prime Medicine valued at $1.8 bln in strong debut (Reuters)
Oct-19-22 09:47PM	Prime Medicine Announces Pricing of Upsized Initial Public Offering (Business Wire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Institutional Ownership

Alphabet Inc.	11.48%
ARK Investment Management LLC	3.93%
BlackRock, Inc.	3.45%
T. Rowe Price Investment Management, Inc.	3.03%
FMR LLC	2.90%
VANGUARD GROUP INC	2.79%
Sumitomo Mitsui Trust Group, Inc.	2.36%
Nikko Asset Management Americas, Inc.	2.36%
Redmile Group, LLC	1.58%
MILLENNIUM MANAGEMENT LLC	1.43%

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Prime Medicine Inc

Target Price and Recommendations

EPS Performance and Forecast

GAAP EPS Performance and Forecast

Revenue Performance and Forecast

Institutional Ownership

Upgrade your FINVIZ experience